In 12 patients with significant coronary artery disease (group I) Therefore, the primary purpose of the present study was to reassess the sedative and hemodynamic effects of diazepam in patients undergoing cardiac catheterization. Since measurements of coronary blood flow are now easily feasible in the cardiovascular laboratory,'4 we have also attempted to determine the coronary and metabolic effects of diazepam in patients with normal and diseased coronary arteries.
neither coronary blood flow nor coronary vascular resistance were modified by diazepam, the fall in LVEDP could be due to a decrease in AP (afterload) and/or in venous return (preload) . The has been found very useful to induce analgesia and amnesia during direct-current cardioversion.'À lthough it is generally accepted that diazepam produces less circulatory depression than morphine, other narcotics and barbiturates,'6 these agents are still used much more commonly to alleviate apprehension and pain in cardiac patients, be it during the course of an acute myocardial infarction or in the cardiovascular laboratory. In the latter clinical situation, this contrasts with the general acceptance of diazepam as an excellent mental relaxant prior to bronchoscopy,4 gastroscopy6 and other procedures. 7', 8 On the other hand, diazepam is frequently prescribed in the management of anginal patients. Since anginal pain is often related to stressful stimuli, the beneficial effects of this tranquilizing drug are thought to be mediated through its action on the psyche. However, recent studies have shown that diazepam increases coronary blood flow and thus enhances left ventricular contractility in dogs during cardiopulmonary bypass.9 10 Hemodynamic studies following diazepam administration in humans have been few and fragmentary." 1-For example, there are to our knowledge no available data on the effects of the drug on left ventricular end-diastolic pressure.
Therefore, the primary purpose of the present study was to reassess the sedative and hemodynamic effects of diazepam in patients undergoing cardiac catheterization. Since measurements of coronary blood flow are now easily feasible in the cardiovascular laboratory,'4 we have also attempted to determine the coronary and metabolic effects of diazepam in patients with normal and diseased coronary arteries.
Methods

Subjects
Twenty unpremedicated subjects undergoing cardiac evaluation for coronary artery disease were studied after an overnight fast. Informed consent was obtained for the additional procedure; however, no information was given concerning the nature of the drug to be studied. Exclusion criteria were as follows: diabetes, valvular heart disease, arterial hypertension (diastolic pressure greater than 105 mm Hg), significant pulmonary disease, therapy with betablocking or other autonomic drugs as well as digitalis or other cardiotropic drugs.
The study was undertaken after left heart and coronary sinus catheterization, prior to left ventriculography and coronary arteriography. Patients were then divided into two groups, according to the presence (group I: 12 patients) or absence (group II: 8 patients) of coronary artery disease, as determined by cinecoronary arteriography. Table 1 summarizes the clinical and biological characteristics of the two groups.
Treatments
The control measurements described below were not carried out until at least 10 min after catheter manipulations in order to achieve a stable basal state. The following measurements were made over a 5 min period: blood samples were withdrawn from central aorta and midcoronary sinus for biochemical determinations; all pressures were recorded; cardiac output was determined and, finally, coronary sinus blood flow was measured. During the last 3 min, expired air was collected for determination of body 02 consumption. After completion of basal measurements, diazepam in a dosage of 0.1 mg/kg body weight was injected as a bolus into an arm vein through the side-arm of an infusion tubing and was flushed immediately to avoid phlebitis.`5 The patient was unaware that the drug was being administered. Measurements were repeated at 5 and 15 Left ventricular and aortic pressures were measured through an end-hole, 100 cm, size 7F, polyethylene catheter (USCI, Billerica, Mass.) passed percutaneously from the femoral artery. A 100 cm, size 8F, Ganz thermodilution catheter* was inserted from the right or left antecubital vein into the main coronary sinus. Catheters were connected to Statham P23Db transducers, which were adjusted so that the zero pressure was at the mid-chest position. Pressures were amplified and recorded on high and normal sensitivity and at paper speed of 100 mm/sec on a mul-tichannel Sanborn photographic recorder. Pressure readings were always the mean of 10 beats. Cardiac output was measured after rapid injection of 5 mg of indocyanine green into the coronary sinus, followed immediately by a saline flush. Central aortic blood was withdrawn by a Harvard infusion pump at a rate of 20 ml/min through a cuvette dye densitometer. Computation of the cardiac output was performed with the use of the Williams formula. 17 Systemic vascular resistance (SVR in dynes-cm -min) was calculated as follows:
where MAP indicates mean aortic pressure in mm Hg, CO is cardiac output in L/min, and 80 is the conversion factor to express resistance in absolute units.
Left ventricular stroke work index (LVSWI in gm/beat/iM2) was determined as follows:
where SI indicates stroke index in ml/beat/m2, MSAP is mean systolic aortic pressure and LVEDP is left ventricular end-diastolic pressure, both in mm Hg. Tension-time index (TTI in mm Hg/sec/min) was measured as follows:
where HR represents heart rate in beats/min, SEP is systolic ejection period in sec/beat and MSAP is mean systolic aortic pressure in mm Hg.
Mean systolic ejection rate (MSER in ml/sec/m2) was calculated as follows:
where SI is the stroke index in ml/beat/m2 and SEP is the systolic ejection period in sec/beat.
Coronary Hemodynamics and Metabolism
Coronary sinus blood flow was measured by the ther- 6 mm Hg at 5 min but this was not significant. PC02 increased significantly (P < 0.001) in both groups at 5 min. There was a corresponding decrease in arterial pH 5 min after diazepam: mean decrease of 0.05 in group I (P < 0.001) and 0.03 in group II (P < 0.05). By 15 min, PO2, PCO2 and pH had returned to control values in both groups, with the exception of PO2 in group II, which was still significantly (P < 0.05) lower than control.
Svstemic Hemodynamic Effects of Diazepam
These data are shown in table 3 for both groups.
Heart Rate There was no change in cardiac rhythm. Only two subjects, with heart rates over 100 beats per min, slowed down after diazepam, from 122 to 98 and 112 to 104 beats/min, respectively.
Pressures
At 5 and 15 min after administration of diazepam, aortic pressures (systolic, diastolic and mean) were significantly lower (P < 0.01) than control values in both groups. Aortic pressures were unchanged in only 3 patients. The observed changes were without clinical correlates and did not require therapy.
Left ventricular end-diastolic pressure (LVEDP) fell significantly in the normal group (group II) from 9.5 to 6.6 mm Hg at 5 min (P < 0.01) and to 6.8 mm Hg at 15 min (P < 0.01). In the coronary artery disease group (group I), LVEDP also decreased from 13.3 to 9.8 mm Hg at 5 min (P < 0.01) and to 9.6 mm Hg at 15 min (P < 0.05). In the latter group, 5 13.9 (P < 0.001) and 14.2 ml/min (P < 0.05), and in group II from 13.5 to 11.6 (P < 0.01) and 11.4 ml/min (P < 0.05).
Basal myocardial lactate extraction was low in 3 patients with normal coronary arteries, and lactate extraction increased in these subjects at 5 and 15 min after diazepam. Of the 12 patients with coronary artery disease, 4 had either a decrease of lactate extraction or abnormal production of lactate at rest. One patient reversed myocardial lactate production to extraction after diazepam and 3 remained unchanged.
Discussion
Diazepam has been widely used in patients with heart disease, either orally to relieve emotional tension or parenterally to induce sedation, analgesiaamnesia and narcosis as a pre-anesthetic agent and during electrocardioversion.1-8
The present study was undertaken to determine 1) whether diazepam was a safe and efficient premedicant agent for cardiac catheterization and coronary Following a simultaneous drop in arterial pressure and cardiac output in individuals with normal coronary arteries, systemic vascular resistances remained unchanged. In patients with coronary artery disease, the basal cardiac output was lower and was unchanged following diazepam injection; the relatively small drop in arterial pressure did not alter systemic vascular resistances in these patients.
Of particular interest was the constant fall in left ventricular end-diastolic pressure (LVEDP). As far as we know, this has not previously been investigated in man. This substantial fall was more obvious when basal LVEDP was elevated in some patients of the coronary artery disease group. A diminution in preload, possibly through a reduced venous return, associated with a fall, although moderate, in aortic pressure or a decrease in afterload could have contributed to the decrease in LVEDP in our patients.
The fall in LVEDP could also be due to increase in contractility and/or increase in coronary blood flow. This appears unlikely, however, since cardiac index was either decreased or unchanged, left ventricular stroke work index was unaltered and neither coronary blood flow nor coronary vascular resistance were modified by diazepam in this study.
As a result of its tendency towards a reduction in cardiac output and aortic pressure, tension-time index and myocardial oxygen consumption were significantly decreased after diazepam. Since total coronary blood flow was not increased, diazepam could most likely be regarded as a nitroglycerin-like agent. Nitroglycerin has been shown to lower arterial pressure, cardiac output, the rate of rise of left ventricular pressure and venous return.21 22 The combination of these effects reduces intracavitary volume of the left ventricle, myocardial wall tension and oxygen requirements. It is also possible that the sedative action of diazepam yielded a more basal resting state, as manifested by a significantly decreased total body oxygen consumption.
Mean myocardial extraction ratio of lactate was unchanged in our patients; in a few individual subjects, lactate extraction was increased or even reversed from production to extraction.
In conclusion, this study demonstrates that diazepam is the agent of choice to produce sedation in patients with heart disease. It causes minimal depression of respiration and has negligible side effects. It has no deleterious effect on the cardiovascular system; on the contrary, its effects tend to bring about an improvement in cardiac function. This should be considered when the drug is used as a premedicant in the cardiovascular laboratory. Although further studies are needed in man, besides its central action, diazepam seems to act directly upon the circulation, its mode of action being similar to that of nitroglycerin but of longer duration.
